← Back to Search

High-risk group (surgery) for Prostate Cancer

N/A
Recruiting
Led By Yoganand Balagurunathan, PhD
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Study Summary

This study is an observational retrospective/ prospective study with diagnosed low/intermediate risk (no-surgery) & high risk (surgery) prostate cancer that are eligible and willing to undergo standard of care (SOC) assessment, annually along with biopsies, bio-fluid collection. Participants will obtain genomic and histological evaluation on their biopsied samples. Study follows SOC collection with additional body fluid collection (blood, urine). Biopsy/surgery will not require additional sample collection

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Disease Progression

Trial Design

2Treatment groups
Experimental Treatment
Group I: Intermediate risk group (no-surgery)Experimental Treatment1 Intervention
Participants diagnosed with pre-biopsy mpMRI.
Group II: High-risk group (surgery)Experimental Treatment1 Intervention
Participants who had radical prostatectomy (RP) with (or with-out) mpMR imaging.

Find a Location

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
543 Previous Clinical Trials
134,982 Total Patients Enrolled
27 Trials studying Prostate Cancer
3,684 Patients Enrolled for Prostate Cancer
Yoganand Balagurunathan, PhDPrincipal InvestigatorMoffitt Cancer Center
Julio Pow-Sang, MDPrincipal InvestigatorMoffitt Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Non-Invasive Biomarkers in Prostate Cancer Disease Management
2023. "Non-Invasive Biomarkers in Prostate Cancer Disease Management". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06144619.
~333 spots leftby Jan 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top